

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

OCI-AML-2

RRID:CVCL_1619

Type: Cell Line

Proper Citation

RRID:CVCL_1619

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1619

Proper Citation: RRID:CVCL_1619

Description: Cell line OCI-AML-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia

Defining Citation: [PMID:2538684](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#), [PMID:36982453](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-AML-2

Synonyms: OCI/AML-2, OCIAML-2, OCI-AML2, OCI/AML2, OCI AML2, OCIAML2, AML-2, Ontario Cancer Institute-Acute Myeloid Leukemia-2

Cross References: BTO:BTO_0004619, CLO:CLO_0008235, EFO:EFO_0006706, CLDB:cl3760, CLDB:cl7059, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BCRJ:0383, BioGRID_ORCS_Cell_line:213, BioSample:SAMN03473106, BioSample:SAMN10988499, cancercellines:CVCL_1619, Cell_Model_Passport:SIDM00446, ChEMBL-Cells:ChEMBL3308300, ChEMBL-Targets:ChEMBL2366220, Cosmic:787466,

Cosmic:910947, Cosmic:975288, Cosmic:1012109, Cosmic:1281344, Cosmic:1319545, Cosmic:1582386, Cosmic:2131551, Cosmic:2306231, Cosmic:2750868, Cosmic-CLP:910947, DepMap:ACH-000113, DSMZ:ACC-99, DSMZCellDive:ACC-99, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, EGA:EGAS00001004741, EGA:EGAS00001004743, GDSC:910947, GEO:GSM482511, GEO:GSM887468, GEO:GSM888548, GEO:GSM1374780, GEO:GSM1446749, GEO:GSM1670295, IARC_TP53:21598, ICLC:HTL01010, LiGeA:CCLE_626, LINCS_LDP:LCL-1065, Lonza:327, PharmacDB:OCIAML2_1183_2019, PRIDE:PXD030304, Progenetix:CVCL_1619, PubChem_Cell_line:CVCL_1619, Wikidata:Q54931741

ID: CVCL_1619

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260913T005647+0000

Ratings and Alerts

No rating or validation information has been found for OCI-AML-2.

No alerts have been found for OCI-AML-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang W, et al. (2026) The interaction between NPMc+ and Orai1 induces abnormal calcium influx to facilitate leukemogenesis. The FEBS journal.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell chemical biology, 33(1), 59.

Pereira-Martins DA, et al. (2026) ??Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Nah J, et al. (2025) Microprotein SMIM26 drives oxidative metabolism via serine-responsive mitochondrial translation. Molecular cell, 85(14), 2759.

Hleihel R, et al. (2025) Retinoic acid disrupts an NPM1c/ROS/SEN3/ARF oncogenic axis in acute myeloid leukemia. Leukemia.

Gotthardt G, et al. (2025) Cysteine-reactive covalent chloro-N-acetamide ligands induce ferroptosis mediated cell death. *EMBO reports*, 26(22), 5501.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. *Research square*.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. *Cell reports. Medicine*, 6(6), 102148.

Tin E, et al. (2025) SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity. *Blood cancer discovery*, 6(3), 217.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. *Cell reports. Medicine*, 5(6), 101592.

Qiao X, et al. (2024) Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. *Molecular cancer*, 23(1), 120.

Cai W, et al. (2024) Augmenting CAR T-cell Functions with LIGHT. *Cancer immunology research*, 12(10), 1361.

Tsamouri LP, et al. (2024) The hydrophobicity of the CARD8 N-terminus tunes inflammasome activation. *Cell chemical biology*, 31(9), 1699.

Mill CP, et al. (2024) Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). *Blood cancer journal*, 14(1), 25.

Wang P, et al. (2024) Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. *Cancer research*, 84(6), 905.

Maru B, et al. (2023) PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy. *Cell reports. Medicine*, 4(9), 101191.

Fiskus W, et al. (2023) Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. *Blood cancer journal*, 13(1), 53.

Miyauchi S, et al. (2023) Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18. *Cell reports*, 42(12), 113560.